Halozyme TherapeuticsHALO +3.19%92 Quick Ratio is 2.33 as of Mar. 2026, which is 55% below its 10-year median of 5.20. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Halozyme Therapeutics ranks worse than 61.85% on this metric.
Halozyme Therapeutics has a quick ratio of 2.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Halozyme Therapeutics's Quick Ratio or its related term are showing as below:
HALO'
s Quick Ratio Range Over the Past 10 Years
Min: 1.17 Med: 5.2 Max: 17.34
Current: 2.33
During the past 13 years, Halozyme Therapeutics's highest Quick Ratio was 17.34. The lowest was 1.17. And the median was 5.20.
HALO's Quick Ratio is ranked worse than 61.85% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs HALO: 2.33
Halozyme Therapeutics (NAS:HALO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Halozyme Therapeutics Quick Ratio Related Terms
Halozyme Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Halozyme Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a Quick Ratio of 2.33 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Halozyme Therapeutics and its competitors. This is 55% below median its historical median of 5.20. Over the past decade, Halozyme Therapeutics' Quick Ratio has ranged from 1.17 to 17.34. According to the industry distribution chart, Halozyme Therapeutics ranks #874 out of 1413 companies in the Biotechnology industry, placing it in the top 61.9%.
Is Halozyme Therapeutics' Quick Ratio too high?
Halozyme Therapeutics' current Quick Ratio of 2.33 is 55% below median its 10-year median of 5.20. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 17.34. The Biotechnology industry median Quick Ratio is 3.60. Halozyme Therapeutics' value of 2.33 is 35.3% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #874 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Quick Ratio compare to IBRX and TECH?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #874 out of 1413 companies for Quick Ratio. This places Halozyme Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.60. Halozyme Therapeutics' value of 2.33 is 35.3% below this benchmark. Historically, Halozyme Therapeutics' own Quick Ratio has ranged from 1.17 to 17.34 over the past decade. While the company's 10-year median is 5.20 vs. the industry median of 3.60, Halozyme Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Quick Ratio of 2.33 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Quick Ratio is 2.33, which is 55% below median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $74.96 — trading 17% below its estimated fair value. The current Quick Ratio is 2.33, which is 55% below median its 10-year median of 5.20 and 35.3% below the Biotechnology industry median of 3.60. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Quick Ratio is 2.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $74.96 is trading 17% below its estimated GF Value™ of $90.32.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Quick Ratio: 2.33 (55% below median its 10-year median of 5.20)
GF Value™: $90.32 vs. price of $74.96 (17% below fair value)
Industry Position: 35.3% below the Biotechnology median (#874 of 1413)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
